How Should We Use Transdermal Fentanyl (TF) for Pain Management in Palliative Care Patients?

Fainsinger RL , Bruera E. What is tolerance? J Pain Sympt Manag (in press).

Calis AK , Kohler DR , Corso DM . Transdermally administered fentanyl for pain management. Clin Pharm 1992; 11: 22–36.

Yee LY , Lopez JR . Transdermal fentanyl. Ann Pharmacother 1992; 26: 1393–1399.

Mosser KH . Transdermal fentanyl and cancer pain. Am Fam Phys 1992; 45: 2289–2994.

Simmonds MA . The role of transdermal drug delivery system in cancer pain management. In Current Concepts in Acute, Chronic and Cancer Pain Management. Syllabus of the Post-Graduate Course, Memorial Sloan-Kettering Cancer Centre. Dec. 8–10, 1993; New York, New York.

Gourlay GK , Kowalski SL , Plummer JL , . The transdermal administration of fentanyl in the treatment of post-operative pain: pharmacokinetics and pharmacodynamic effects. Pain 1989; 37 (2):193–202.

Varvel JR , Shafer SL , Hwang SS , . Absorption characteristics of transdermally administered fentanyl. Anesthes 1989; 70 (6):928–934.

Plesia PM , Kramer TH , Linford J , Hamuroff SR . Transdermal fentanyl: pharmacokinetics and preliminary clinical evaluation. Pharmacother 1989; 9 (1):2–9.

Portenoy RK , Southam MA , Gupta SK , . Transdermal fentanyl for cancer pain. Anesthes 1993; 78: 36–43.

Esteve M , Levron JC , Flaisler B , . Does ageing modify pharmacokinetics of transdermal fentanyl? Anesthes 1991; 75: a705.

Miser AW , Narang PK , Dothage JA , . Transdermal fentanyl for pain control in patients with cancer. Pain 1989; 37: 15–21.

Simmonds MA , Richenbacher J. Transdermal fentanyl: long-term analgesic studies. J Pain Sympt Manag 1992; 7: S36–S39.

Ahmedzai S , Allan E , Fallon M , . Transdermal fentanyl in cancer pain. J Drug Dev 1994; 6 (3):93–97.

Fainsinger RL , Miller MJ , Bruera E. Use of transdermal faitanyl in a palliative care program. Presented at the 10th International Congress on Care of the Terminally Ill. Montreal, Canada, Sept. 17–21, 1994.

Payne R , Chandler S , Einhaus M. Guidelines for the clinical use of transdermal fentanyl. Anti-Cancer Drugs 1995; 6 (3):50–53.

Patt RB , Hogan LA . Comment: transdermal fentanyl. Ann Pharmacother 1993; 27: 795–796.

Korte W , Morant R. Transdermal fentanyl in uncontrolled cancer pain; titration on a day-to-day basis as a procedure for safe and effective dose finding — a pilot study in 20 patients. Support Care Cancer 1994; 2: 123–127.

Korte W , de Stoutz N , Morant R. Transdermal fentanyl should be titrated on a day-to-day basis in well-controlled patients with uncontrolled cancer pain. Support Care Cancer 1995; 3: 355.

Brooks D. Day-to-day titration of transdermal fentanyl is unwise. Support Care Cancer 1995; 3: 210.

Korte W , Morant R. Reply. Support Care Cancer 1995; 3: 210–211.

Patt RB , Lustik S , Litman RS . The use of transdermal fentanyl in a six-year-old patient with neuroblastoma and diffuse abdominal pain. J Pain Sympt Manag 1993; 8: 317–319.

MacDonald N. Commentary. J Pain Sympt Manag 1993; 8: 320–321.

Patt RB . Response. J Pain Sympt Manag 1993; 8: 322–323.

Hanks GW , Fallon MT . Transdermal fentanyl in cancer pain: Conversion from oral morphine. J Pain Sympt Manag 1995; 10: 87.

Duragesic Product Monograph. Janssen Pharmaceutica, Mississauga, Ontario. Revised edition February 3, 1995.

Zenz M , Donner B , Strumpf M. Withdrawal symptoms during therapy with transdermal fentanyl (fentanyl TTS)? J Pain Sympt Manag 1994; 9: 54–55.

Higgs CMB , Vella-Brincat J. Withdrawal with transdermal fentanyl. J Pain Sympt Manag 1995; 10: 4–5.

Kunz KM , Theisen JA , Schroeder ME . Severe episodic pain: management with sublingual sufentanil. J Pain Sympt Manag 1993; 8: 189.

Fainsinger RL , Bruera E. The management of dehydration in terminally ill patients. J Palliat Care 1994; 10: 55–59.

Bruera E , Velasco-Leiva A , Spachynski K , . The use of the Edmonton Injector for parenteral opioid management of cancer pain: a study of 100 consecutive patients. J Pain Sympt Manag 1993; 8: 525–528.